Clinical Trials Directory

Trials / Completed

CompletedNCT02526173

DHACM in Robotic Assisted Laparoscopic Prostatectomy (RALP)

A Prospective Randomized Clinical Trial Using Dehydrated Human Amnion/Chorion Membrane (dHACM) in Nerve Sparing Robotic Assisted Laparoscopic Radical Prostatectomy (RALP) - Effect on Potency Outcomes

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
230 (actual)
Sponsor
MiMedx Group, Inc. · Industry
Sex
Male
Age
40 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The investigators will examine the beneficial impacts of applying of dHACM on the preserved neurovascular bundles (cavernosal nerves) and the prostate bed during robotic assisted laparoscopic prostatectomy. Such application can result in promotion of soft tissue healing and reduction of inflammation at the operative site and thus an acceleration of return of potency regulating cavernosal nerves.

Detailed description

The overall objective of this study is to evaluate the effectiveness of dehydrated human amnion/chorion membrane (dHACM) in reducing neurovascular bundle inflammation in prostate cancer patients undergoing bilateral full nerve sparing robotic assisted laparoscopic radical prostatectomy (RALP). Specifically, this study compares potency outcomes in patients who had full nerve sparing RALP procedures with dHACM application to the neurovascular bundles to that of full nerve sparing RALP without dHACM application to neurovascular bundles. Patients will be randomized to one of two possible treatment groups: * Group 1 - Treatment Group ( Full Nerve Sparing RALP + AmnioFix®) * Group 2 - Control Group ( Full Nerve Sparing RALP alone)

Conditions

Interventions

TypeNameDescription
PROCEDURERALP using full nerve sparing techniqueRALP using full nerve sparing technique
OTHERdHACM Application2x12 sheet of dHACM applied to the neurovascular bundle

Timeline

Start date
2015-10-01
Primary completion
2018-06-21
Completion
2018-06-21
First posted
2015-08-18
Last updated
2018-09-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02526173. Inclusion in this directory is not an endorsement.